Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RORoivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV)

NASDAQ Global Market · Currency in USD
$36.49 ▼ -0.96 (-2.56%)
At close: Oct 23, 4:00 PM ET. Market closed.
$37.47 ▲ +0.98 (+2.69%)
After hours: Oct 23, 7:51 PM ET

Summary

Previous Close
$37.45
Open
$37.23
Day's Range
$36.36 – $37.42
52 Week Range
$18.27 – $42.50
Volume
8,225,361
Avg. Volume
7,066,384
Market Cap
$26.36B
Beta (5Y Monthly)
1.10
PE Ratio (TTM)
--
EPS (TTM)
-$0.37
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$47.71

Profile: Roivant Sciences Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
721
CEO
Matthew Gline

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.37 · Revenue est. $3.74M
DateEst.Actual
Aug 6, 2026-$0.30-$0.33Miss
May 20, 2026-$0.29-$0.28Beat
Feb 6, 2026-$0.30-$0.24Beat
Nov 10, 2025-$0.32-$0.20Beat
Aug 11, 2025-$0.25-$0.25Miss
May 29, 2025-$0.26-$0.29Miss

Analyst view

Consensus price target
$47.71 ▲ +30.7%
Range $41.00 – $55.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on ROIV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.